Program
rinvecalinase alfa
Also written as “DM199” and “Recombinant human tissue kallikrein”.
Its studies are mostly in Ischemic Stroke · Kidney Diseases · Pre-Eclampsia · Renal Insufficiency, Chronic · Stroke, led by DiaMedica Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DiaMedica Therapeutics | 71 open or running | phase 3since Sep 3, 2021 | Apr 23, 2013 | Dec 2026phase 3 · NCT05065216 |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2013First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01845064 · 98 enrolled · Netherlands
- Aug 8, 2016Phase 1 study in StrokeNCT02868996 · 36 enrolled · Australia
- Sep 18, 2017Phase 2 study in Ischemic StrokeNCT03290560 · 92 enrolled · Australia
- Jan 3, 2019Phase 1 study in Renal Insufficiency, ChronicNCT03795389 · 33 enrolled · United States
- Oct 8, 2019Phase 2 study in Kidney DiseasesNCT04123613 · 84 enrolled · United States
- Sep 3, 2021Phase 3 study in StrokeNCT05065216 · 728 planned · United States, Belgium, Canada and more
- Mar 4, 2025No phase study in Pre-EclampsiaNCT06875141
Ahead
- Dec 2026Primary completion: phase 3 study in StrokeNCT05065216
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06875141Pre-Eclampsia | – | Withdrawn | May 2025 | 0 |
| NCT05065216Stroke · United States, Belgium, Canada and more | 3 | Recruiting | Dec 2026 | 728 |
| NCT04123613Kidney Diseases · United States | 2 | Completed | Mar 16, 2022 | 84 |
| NCT03795389Renal Insufficiency, Chronic · United States | 1 | Completed | Jul 21, 2019 | 33 |
| NCT03290560Ischemic Stroke · Australia | 2 | Completed | Jan 23, 2020 | 92 |
| NCT02868996Stroke · Australia | 1 | Completed | Mar 2017 | 36 |
| NCT01845064Diabetes Mellitus, Type 2 · Netherlands | 2 | Completed | Sep 2014 | 98 |
How it is read
Names in the registry
- “DM199”, 4 entries
- “Recombinant human tissue kallikrein”, 3 entries
Conditions, from the studies’ own filings
- Ischemic Stroke, 2 studies
- Kidney Diseases, 1 study
- Pre-Eclampsia, 1 study
- Renal Insufficiency, Chronic, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.